Key result
Oral administration of cHPMPC delayed the onset of clinical signs and significantly reduced viral titres in blood and tissues of pigs infected with African swine fever virus.
Why the study?
African swine fever virus causes severe haemorrhagic disease with high fatality, and no vaccine is widely available.
Does cHPMPC inhibit African swine fever virus replication in vitro and in vivo?
Population
Primary porcine macrophages and pigs infected with African swine fever virus
Comparison
cHPMPC administration vs untreated or timing of addition
Design
In vitro and in vivo study
Authors
Loading...
Hypothesis-generating for oral cHPMPC in ASFV; larger trials needed before veterinary or outbreak use.
Does cHPMPC inhibit African swine fever virus replication in vitro and in vivo?
cHPMPC demonstrates promising antiviral activity against African swine fever virus in vitro and in vivo, suggesting potential for further development to control outbreaks.
Goulding et al. (2022) studied African swine fever virus (ASFV) infection. cyclic cidofovir (cHPMPC) was evaluated on Onset of clinical signs and viral titres in blood and tissues. Oral administration of cHPMPC delayed the onset of clinical signs and significantly reduced viral titres in blood and tissues of pigs infected with African swine fever virus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: